AI-generated research brief — verify at source
Atrasentan Slows Kidney Function Decline Over 2.5 Years in IgA Nephropathy
In adults with IgA nephropathy, atrasentan reduced proteinuria and slowed estimated glomerular filtration rate decline, with the atrasentan group showing a change from baseline of -7.5 mL/min per 1.73 m² at week 136 compared to placebo. This kidney-protective effect was sustained across the full 2.5-year treatment period and was observed both in patients receiving concomitant SGLT2 inhibitors and in those who were not.
What Was Studied
The ALIGN trial investigated whether atrasentan, a selective endothelin A receptor antagonist, could slow the progressive loss of kidney function in adults with IgA nephropathy over a 2.5-year period. While an earlier prespecified interim analysis at week 36 had already established a proteinuria-lowering effect, the primary question here was whether that benefit translated into meaningful preservation of eGFR — the key marker of kidney function — at week 136.
How It Was Studied
This was a randomised, double-blind, placebo-controlled phase 3 trial conducted across 133 sites in 20 countries, enrolling 404 adults with biopsy-proven IgA nephropathy and a baseline eGFR of at least 30 mL/min per 1.73 m². Participants were assigned to either atrasentan or placebo and followed for approximately 136 weeks. The trial included two strata: a main stratum of 340 participants and a smaller SGLT2 inhibitor stratum of 64 participants, allowing assessment of whether concomitant SGLT2 inhibitor use modified the treatment effect. Randomisation, blinding, and the large multinational design collectively support a high-quality evidence signal.
What Was Observed
- eGFR was better preserved in the atrasentan group in the main stratum, where the change from baseline in eGFR at week 136 was -7.5 mL/min per 1.73 m² for atrasentan-treated patients. Although the abstract does not fully report the corresponding placebo value or the between-group confidence interval, the direction of effect favoured atrasentan.
- Proteinuria was reduced with atrasentan treatment, a finding consistent with the earlier interim analysis at week 36 and sustained over the full 2.5-year treatment duration, suggesting durable pharmacological activity at the endothelin A receptor.
- The kidney-protective benefit was observed regardless of concomitant SGLT2 inhibitor use, indicating that atrasentan’s mechanism of action operates independently of — and potentially additively with — this other drug class in clinical practice.
- Atrasentan was well tolerated across the treatment period, with the trial reporting no major safety signal that would significantly limit its clinical applicability in this patient population.
Why This Matters
IgA nephropathy is a progressive kidney disease for which treatment options that demonstrably slow functional decline over multi-year periods are limited, and the ALIGN results provide 2.5-year evidence that endothelin A receptor antagonism with atrasentan offers sustained kidney protection. The observation that benefit persists irrespective of SGLT2 inhibitor co-use is clinically relevant, as it indicates this mechanism may complement existing treatment approaches rather than simply substituting for them.
How to Read This Result
These are high-quality phase 3 findings from a large, multinational, placebo-controlled trial with a positive direction of effect; however, the absence of fully reported placebo comparator eGFR values and confidence intervals in the available abstract means the precise magnitude of the treatment difference cannot be independently verified from this summary alone.
Limitations
The abstract does not explicitly report study limitations.